Global Alzheimers Disease Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2024

  • receipt Report ID : 157339
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 122
  • list Pharmaceuticals and Healthcare

Alzheimer’s disease is a neurodegenerative, progressive, non-reversible disorder. Alzheimer’s disease is caused due to abnormal functioning of brain cells i.e. failure of synaptic transmission, resulting in the loss of cognitive functions. Some of the signs and symptoms of alzheimer’s disease are memory loss, insomnia, repetitive movements, agitation, anxiety, depression and loss of reasoning abilities. All memory and mental functioning may be lost in advanced stages of the disease. Alzheimer’s disease may lead to death. According to National Institute of Aging, Alzheimer’s disease is the common form of dementia. 

Scope of the Report:

This report studies the Alzheimers Disease Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Alzheimers Disease Therapeutics market by product type and applications/end industries.

Population aging across the globe is a major factor driving the market for Alzheimer’s therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in number of aged population, and is associated with increased prevalence of chronic diseases like dementia. Therapies for AD offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease advancement. Thus, the magnitude of the affected population and lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers. However, identification of the primary reasons and mechanisms involved in AD are is limited. Drug manufacturers have been unable to validate significant clinical benefits of treatment for a numerous of new compounds due to strict regulations. One of the significant trend observed in this market is collaboration of the existing players.  Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates which is further expected to propel the demand.

North America dominates the global market for alzheimer’s disease therapeutics due to large number of aging population. Asia followed by the Europe are expected to show high growth rates in the next five years in the global alzheimer’s disease therapeutics market. China and India are expected to be the fastest growing alzheimer’s disease therapeutics markets in Asia-Pacific region. Some of the key driving forces for alzheimer’s disease therapeutics market in emerging countries are increasing R&D investment, large pool of patients and improvement of healthcare infrastructure. 

The global Alzheimers Disease Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Alzheimers Disease Therapeutics.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

F. Hoffmann-La Roche

Merck

Pfizer

Novartis

Eisai

Actavis

Daiichi Sankyo

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Biomarkers

Cholinesterase Inhibitors

NMDA Receptor Antagonists

Market Segment by Applications, can be divided into

Hospitals

Clinics

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Alzheimers Disease Therapeutics Market Overview

1.1 Product Overview and Scope of Alzheimers Disease Therapeutics

1.2 Classification of Alzheimers Disease Therapeutics by Types

1.2.1 Global Alzheimers Disease Therapeutics Revenue Comparison by Types (2017-2023)

1.2.2 Global Alzheimers Disease Therapeutics Revenue Market Share by Types in 2017

1.2.3 Biomarkers

1.2.4 Cholinesterase Inhibitors

1.2.5 NMDA Receptor Antagonists

1.3 Global Alzheimers Disease Therapeutics Market by Application

1.3.1 Global Alzheimers Disease Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Hospitals

1.3.3 Clinics

1.4 Global Alzheimers Disease Therapeutics Market by Regions

1.4.1 Global Alzheimers Disease Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Alzheimers Disease Therapeutics Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Alzheimers Disease Therapeutics Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Alzheimers Disease Therapeutics Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Alzheimers Disease Therapeutics Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Alzheimers Disease Therapeutics Status and Prospect (2013-2023)

1.5 Global Market Size of Alzheimers Disease Therapeutics (2013-2023)

2 Manufacturers Profiles

2.1 F. Hoffmann-La Roche

2.1.1 Business Overview

2.1.2 Alzheimers Disease Therapeutics Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 F. Hoffmann-La Roche Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.2 Merck

2.2.1 Business Overview

2.2.2 Alzheimers Disease Therapeutics Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Merck Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.3 Pfizer

2.3.1 Business Overview

2.3.2 Alzheimers Disease Therapeutics Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Pfizer Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.4 Novartis

2.4.1 Business Overview

2.4.2 Alzheimers Disease Therapeutics Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Novartis Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.5 Eisai

2.5.1 Business Overview

2.5.2 Alzheimers Disease Therapeutics Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Eisai Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.6 Actavis

2.6.1 Business Overview

2.6.2 Alzheimers Disease Therapeutics Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Actavis Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.7 Daiichi Sankyo

2.7.1 Business Overview

2.7.2 Alzheimers Disease Therapeutics Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Daiichi Sankyo Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

3 Global Alzheimers Disease Therapeutics Market Competition, by Players

3.1 Global Alzheimers Disease Therapeutics Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Alzheimers Disease Therapeutics Players Market Share

3.2.2 Top 10 Alzheimers Disease Therapeutics Players Market Share

3.3 Market Competition Trend

4 Global Alzheimers Disease Therapeutics Market Size by Regions

4.1 Global Alzheimers Disease Therapeutics Revenue and Market Share by Regions

4.2 North America Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

4.3 Europe Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

4.5 South America Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

5 North America Alzheimers Disease Therapeutics Revenue by Countries

5.1 North America Alzheimers Disease Therapeutics Revenue by Countries (2013-2018)

5.2 USA Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

5.3 Canada Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

5.4 Mexico Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

6 Europe Alzheimers Disease Therapeutics Revenue by Countries

6.1 Europe Alzheimers Disease Therapeutics Revenue by Countries (2013-2018)

6.2 Germany Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

6.3 UK Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

6.4 France Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

6.5 Russia Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

6.6 Italy Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Alzheimers Disease Therapeutics Revenue by Countries

7.1 Asia-Pacific Alzheimers Disease Therapeutics Revenue by Countries (2013-2018)

7.2 China Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

7.3 Japan Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

7.4 Korea Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

7.5 India Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

8 South America Alzheimers Disease Therapeutics Revenue by Countries

8.1 South America Alzheimers Disease Therapeutics Revenue by Countries (2013-2018)

8.2 Brazil Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

8.3 Argentina Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

8.4 Colombia Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Alzheimers Disease Therapeutics by Countries

9.1 Middle East and Africa Alzheimers Disease Therapeutics Revenue by Countries (2013-2018)

9.2 Saudi Arabia Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

9.3 UAE Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

9.4 Egypt Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

9.5 Nigeria Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

9.6 South Africa Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

10 Global Alzheimers Disease Therapeutics Market Segment by Type

10.1 Global Alzheimers Disease Therapeutics Revenue and Market Share by Type (2013-2018)

10.2 Global Alzheimers Disease Therapeutics Market Forecast by Type (2018-2023)

10.3 Biomarkers Revenue Growth Rate (2013-2023)

10.4 Cholinesterase Inhibitors Revenue Growth Rate (2013-2023)

10.5 NMDA Receptor Antagonists Revenue Growth Rate (2013-2023)

11 Global Alzheimers Disease Therapeutics Market Segment by Application

11.1 Global Alzheimers Disease Therapeutics Revenue Market Share by Application (2013-2018)

11.2 Alzheimers Disease Therapeutics Market Forecast by Application (2018-2023)

11.3 Hospitals Revenue Growth (2013-2018)

11.4 Clinics Revenue Growth (2013-2018)

12 Global Alzheimers Disease Therapeutics Market Size Forecast (2018-2023)

12.1 Global Alzheimers Disease Therapeutics Market Size Forecast (2018-2023)

12.2 Global Alzheimers Disease Therapeutics Market Forecast by Regions (2018-2023)

12.3 North America Alzheimers Disease Therapeutics Revenue Market Forecast (2018-2023)

12.4 Europe Alzheimers Disease Therapeutics Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Alzheimers Disease Therapeutics Revenue Market Forecast (2018-2023)

12.6 South America Alzheimers Disease Therapeutics Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Alzheimers Disease Therapeutics Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Alzheimers Disease Therapeutics Picture

Table Product Specifications of Alzheimers Disease Therapeutics

Table Global Alzheimers Disease Therapeutics and Revenue (Mil

Please fill the form below, to recieve the report sample


+1